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Abstract
Background: To evaluate the feasibility and clinical preliminary results of weekly cisplatin and volumetric-modulated arc
therapy to the pelvis with simultaneous integrated boost to macroscopic disease in a cohort of elderly patients. Materials and
Methods: Inclusion criteria of this prospective study were age 70 years, Karnofsky performance status 70 to 100, locally
advanced histologically proven squamous cervical carcinoma, and patients unable to undergo brachytherapy. Radiation doses
prescribed were 66 Gy to the macroscopic disease and 54 Gy to the pelvic nodes in 30 fractions. Weekly cisplatin dose was
40 mg/mq. Results: A total of 30 patients were recruited. Median follow-up was 32 months (range: 8-48 months). Median age was
72 years (range: 70-84 years). The 3-year overall survival and local control were 93% and 80%, respectively. The median time to
progression was 24 months (range: 6-30 months). Analyzing clinical outcome grouping based on the stage of disease, II versus III,
the 3-year overall survival was 100% and 85%, respectively. The 3-year local control was 91% for stage II and 67% for stage III.
Acute and late toxicities were acceptable without severe events. Conclusion: Weekly cisplatin and volumetric-modulated arc
therapy–simultaneous integrated boost for radical treatment of advanced cervical cancer in the current cohort of elderly patients
were feasible. Long-term results and prospective randomized trials are advocated.
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Introduction
In patients affected by locally advanced cervical carcinoma,
definitive chemoradiotherapy (ChT-RT) guarantees long-term
local control (LC) rates ranging between 88% and 95% for
stage IB, 70% and 80% for stage II, and 30% and 40% for stage
III. The combination of external beam radiotherapy (EBRT)
and brachytherapy (BRT) represents the mainstay in the
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primary treatment of patients with cervical cancer.1-3 Unfortu-
nately, compared to EBRT, BRT is less widespread in radiation
departments. Additionally, some criticisms are related to the
feasibility of BRT, including: (1) a long learning curve for
radiation oncologist,4 (2) some patients eligible to radiotherapy
(RT) are not able to receive BRT for some contraindications to
invasive procedures, and (3) some patients refuse to move in
other RT facilities for logistic problems (especially elderly
patients). Thus, in all these cases, an alternative RT option
should be offered. Several authors have already investigated
the use of different EBRT techniques as a reasonable option
after EBRT to the pelvis when BRT was not feasible.5-7
Volumetric-modulated arc therapy (VMAT) showed a great
potential for highly conformal dose to target volume, maintain-
ing a low–moderate toxicity profile in pelvic irradiation.8,9
The aim of the present study was to evaluate the feasibility
and clinical preliminary results of weekly cisplatin and VMAT
to the pelvis with simultaneous integrated boost (SIB) to
macroscopic disease in a cohort of elderly patients.
Materials and Methods
In our institution, a prospective study was approved by the
internal review board (RT-02/2011). Inclusion criteria were
age 70 years old, Karnofsky performance status of 70 to
100, locally advanced histologically proven squamous cervical
carcinoma, patients refusing BRT or not suitable to invasive
treatment procedures due to comorbidities, and a signed spe-
cific informed consent.
All patients recruited in the study accepted the RT protocol
proposed: a dose of 66 Gy to the macroscopic disease and
54 Gy to the pelvis in 30 fractions with SIB-VMAT technique.
According to the study protocol, all patients were staged with
gynecologic examination, pelvic magnetic resonance imaging
(MRI) with contrast, and 18fluorodeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) before
treatment. The stage system used was the International Feder-
ation of Gynecology and Obstetrics 2009 criteria. Clinical
outcomes and toxicity data according to the Common Termi-
nology Criteria for Adverse Events (CTCAE version 4.0) were
collected prospectively.
Treatment Procedure
After patient immobilization in supine position by Combifix
frame (Civco Inc., Orange City, Iowa, US), CT planning of
abdomen–pelvis (3-mm-thickness slice) without intravenous
contrast media was performed. The lower limit of the scanned
area was set to 2 cm below the lower limit of the lesser tro-
chanter, and the upper limit was the L2-L3 interspace. Patients
were simulated and treated with full bladder: they were asked
to drink 500 mL of water 30 minutes before CT planning and
before each treatment session. If the rectum was abnormally
full or distended, CTs were carried out following enema. The
18FDG PET/CT and MRIs were merged separately with the CT
planning to define the clinical target volume-SIB (CTV-SIB),
using intermediate/high signal seen on T2-weighted MRIs and
including the hypermetabolic areas of 18FDG PET/CT (primary
tumor or pelvic nodes). The planning target volume-SIB
(PTV-SIB) was generated using a 5-mm isotropic expansion
on CTV-SIB. A total dose of 66 Gy in 30 fractions was pre-
scribed to PTV-SIB.
According to consensus guidelines for the delineation of
CTV for intensity-modulated pelvic RT in the treatment of
cervix cancer,10 CTV was defined including (1) CTV-SIB;
(2) cervix, if not already included within CTV-SIB contour;
(3) uterus, parametrium, including ovaries; (4) the entire
mesorectum if uterosacral ligament was involved; (5) the upper
two-thirds of the vagina; and (6) locoregional lymph nodes:
common, internal, and external iliac, obturator, and presacral.
Isotropic CTV to PTV margins of 8 mm to primary tumor
(cervical cancer region) and 7 mm to nodal region were
adopted. A total dose of 54 Gy in 30 fractions was prescribed
to PTV. Organs at risk (OARs) were bladder, bowel defined as
intestinal cavity, rectum, and femoral heads. Radiotherapy
was delivered 1 fraction/d for 5 d/wk. Before each daily ses-
sion, patients were submitted to an image-guided radiotherapy
(IGRT) procedure by means of a daily kV cone-beam CT
(CBCT) to check and to correct setup errors. Radiotherapy
was delivered concomitantly with the administration of
weekly cisplatin 40 mg/mq, if no individual contraindications
(neutrophil count <1.5 109/L and/or a platelet count <100
109/L and/or hemoglobin level 110 g/L and/or serum crea-
tinine >140 mm/L).
Planning Objectives
RapidArc (Varian Inc, Palo Alto, California) VMAT treat-
ments by two 360 arcs with 6-MV photon beams from a Tril-
ogy (Varian Inc) linac were optimized by PRO (version
10.0.28; Varian Inc) algorithm. Necessary constraints for plan-
ning approval in terms of target dose coverage were a PTV
volume 95% receiving a dose 95% of the prescribed dose
for both PTV and PTV-SIB and a near-maximum dose to
PTV-SIB not >70.6 Gy. The near-maximum dose to PTV was
minimized while giving priority to PTV-SIB dose coverage.
The following OARs constraints were adopted: maximum
dose to 1 mL (Dmax) of the rectum, bladder, and intestinal
cavity 66 Gy; Dmax 50 Gy for femoral heads; V46.5 Gy
< 50% and V64.5 Gy < 15% for rectum; V46.5 Gy < 50% and
V64.5 Gy < 20% for bladder; and V40 Gy < 30% for intestinal
cavity.
Dose calculation was then performed by AAATM (version
10.0.28; Varian Inc) algorithm, using a dose calculation grid
size equal to 2 mm and by including CT-based heterogeneity
corrections.
Follow-Up
During RT, physical examination and complete blood count
were performed weekly. Gynecological examination including
Pap-test was usually performed every 3 to 4 months for the first
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2 years, every 6 months for the next 3 years. The 18FDG
PET/CT and pelvic MRI were performed during the first year
after RT. From the second year after RT, CT scan or 18FDG
PET/CT was performed when clinically indicated.
Complete response (CR) was defined as the disappearance
of the lesions at imaging; a reduction more than 30% was
considered partial remission; no modification was considered
stable disease; and any growing lesion not imputable clearly to
fibrosis was reported as progression of disease, according to
Response Evaluation Criteria in Solid Tumors.11 Reduced
metabolic activity was evaluated based on decreases in Stan-
dardized Uptake Value (SUV) from pre- to posttreatment and
on the SUV measurements obtained in each 18FDG PET/CT
examination. A complete metabolic response was defined as
the complete normalization of SUV in the target lesions, with
mean lesion SUV being similar to that of the surrounding tis-
sue. Progressive metabolic disease was defined as an increase
of at least 30% in the mean SUV of target lesions. A reduction
of at least 30% in the mean SUV of target lesions was consid-
ered a partial metabolic response, whereas an increase or
decrease in SUV that did not exceed 30% was indicative of
stable metabolic disease.12
Statistical Analyses
Local control and overall survival (OS) rates were estimated
using the Kaplan-Meier method. Local control was defined
from the beginning of the treatment to the locoregional relapse
date. Local recurrence was defined as any relapse in the field
(pelvis or cervix). Time to progression (TTP) was considered
from the beginning of the treatment to the time of any recur-
rence or distant metastasis. The OS was calculated from the
date of diagnosis to the death or last follow-up date. Statistical
analyses were carried out using R-software 3.1.2 version.
Results
From September 2011 to April 2015, 30 patients affected by
histologically proven squamous cervical carcinoma were
recruited in the protocol. The median follow-up was 32 months
(range: 8-50 months). The median age was 72 years (range:
70-84 years). The Karnofsky performance status ranged
between 80 and 100. No patient interrupted the RT course.
Conversely, in 5 patients, weekly cisplatin was not adminis-
tered as programmed in the protocol (in 3 cases for age
80 years, in 1 case for renal dysfunction pretreatment, and
in 1 case for renal dysfunction during treatment). Patients’
baseline characteristics are detailed in Table 1.
At the time of the analysis, the 3-year OS and LC were 93%
and 80%, respectively (Figure 1). Only 1 cancer-related death
was recorded in a patient with a stage III disease. Four recur-
rences in cervix were observed in 3 cases of stage III group and
in 1 case of stage II group.
The probabilities of local failure at 1, 2, and 3 years were
6.7%, 13.3%, and 13.3%, respectively. The probabilities of
distant progression at 2 and 3 years were 13.3% and 16.7%,
respectively. The median TTP was 24 months (range: 6-30
months). Sites of distant metastases were liver (in 2 cases of
stage III group), lung (in 1 case of stage III group), and abdo-
men nodes (in 2 cases of stage II group). One patient with
abdomen node metastases was not a candidate to concomitant
cisplatin for advanced age (>80 years); in a patient with liver
metastases, cisplatin was interrupted after 2 cycles for renal
dysfunction. Figure 2 shows an example of durable CR at
18FDG PET/CT.
Analyzing clinical outcomes grouping based on the stage of
disease, stage II versus stage III, the 3-year OS was 100% and
85%, respectively. The 3-year LC was 91% for stage II and
67% for stage III (Figure 3). Toxicity was registered in all
cases. Table 2 reports acute/late adverse events recorded,
according to CTCAE version 4.0. Organs at risk constraints
were respected in the majority of cases.
Discussion
In locally advanced cervical cancer, BRT in combination with
pelvic EBRT allows to deliver high doses to target volumewhile
sparing bladder and rectum, reaching very encouraging clinical
outcomes and minimizing the risk of serious adverse events.2,3
In the past years, the possibility to omit BRT in this setting of
disease, delivering the entire treatment coursewith EBRTalone,
has been explored with poor outcomes.13 Recent advances in
EBRT are facing the inevitable question whether the intensity-
modulated techniques could represent a potential alternative to
BRT in the management of cervical cancer. Volumetric-
modulated arc therapy, a rotational intensity-modulated RT
Table 1. Patients Baseline Characteristics.
Parameters No. (%)
Diabetes 10 (33)
Hypertension 12 (36)
Reasons for omission of brachytherapy
Patents refusal (for logistic problems to move in
other RT facilities or because of virginity)
25 (83)
Vaginal stenosis 5 (17)
Histology
Squamous cell carcinoma 30 (100)
Grading
G1 3 (10)
G2 18 (60)
G3 9 (30)
FIGO 2009 stage
II 16 (53)
III 14 (47)
Pelvic nodes statusa
Positive 8 (27)
Negative 22 (73)
Weekly cisplatin 25 (83)
Median overall treatment time, days 42 (range: 42-44)
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics;
FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron
emission tomography.
aAt imaging (MRI and/or 18FDG-PET-scan).
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(IMRT), potentially offers an optimal conformal dose to the
target with improved homogeneity and conformity in several
settings, including pelvis.14,15 The VMAT planning studies
showed a short delivery time that could reduce the intrafraction
uncertainties and a satisfactory OARs sparing, with an average
12% integral dose reduced to healthy tissues.9,16 To date, the
general consensus is that the intensity-modulated techniques
will not replace the role of BRT in cervical cancer due to the
clear advantages of BRT in terms of organ immobilization with
steep dose gradients and highly conformal dose distribution.
However, the American Brachytherapy Society Gynecologic
Cervical Cancer Task group has developed general criteria for
the management of cervical cancer.17 There are situations in
which BRT cannot be feasible, such as prior RT with BRT and
life expectancy <6 months.
The present study was designed to evaluate an alternative
option for patients who refused or were not able to receive BRT
(most of them due to logistic problems to move in other distant
RT facilities or because of virginity or because of vaginal
stenosis). Generally, in many countries, due to the few centers
with expertise in BRT, patients are generally sent to a reference
center for BRT boost after external IMRT/3-dimensional (3D)
EBRT, and this is our policy. Patients eligible for the current
study were not candidate to BRT for the reasons detailed in
Table 1. To our knowledge, this is the first report for elderly
patients affected by locally advanced cervical cancer in terms
of RT technique and adopted schedule. The findings of the
present analysis appear promising in terms of preliminary clin-
ical outcomes and tolerability. Thus, the current schedule of
weekly cisplatin and VMAT-SIB for the radical treatment of
advanced cervical cancer could be a viable therapeutic option
in the elderly setting, here defined as age 70 years. In fact, in
the population of study, the 3-year OS and LC were 93% and
80%, respectively. Although the data are preliminary, these
results seem to be unexpected when compared to what is sug-
gested in the literature.2,3 In fact, it is well known that in the
treatment of cervical cancer, the LC rates are related to the
biologically equivalent dose: high doses (80-95 Gy to the pri-
mary tumor) administered over a short time (inferior to
50-55 days) significantly impact on LC and OS.
The rationale to deliver the here reported radiation doses
derives from the assessment that in the radical treatment of
squamous cell carcinoma in other anatomic district, for exam-
ple, in head and neck, 66 Gy in 30 fractions represents an
effective schedule of radical RT.18 Moreover, the SIB
approach, adopted to irradiate a prophylactic volume with con-
ventional daily fractions while simultaneously treating the pri-
mary tumor or positive pelvic lymph nodes with a higher dose
per fraction, reduces the overall treatment time. Hypotheti-
cally, this latter aspect could have a potential effect on cellular
repopulation. Preclinical data suggest that modest increase in
fraction size improves the cells killing in patients having cer-
vical cancer treated with concurrent ChT-RT.19 The choice of
isotropic CTV to PTV margins of 8 mm to primary tumor
(cervical cancer region) was related to the daily IGRT proce-
dure by means of daily kV-CBCT to check and to correct setup
errors. A recent study, designed to analyze the nature and
extent of the intrafraction motion of the cervix–uterus and,
Figure 1. Kaplan-Meier curves for the population of the study: (A) overall survival, (B) local control.
Figure 2. An example of complete response at 18FDG PET/CT during
follow-up: (A) pretherapy, (B) posttherapy. FDG, 18-fluorodeoxyglu-
cose positron emission tomography–computed tomography.
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thus, their contributions to the CTV to PTV margins, estimated
that the mean intrafraction cervix–uterus displacements were
up to 5.8 mm posteriorly and up to 4.9 mm cranially.20 Addi-
tionally, a uniform 3D PTV expansion of 7 mm is recom-
mended for the lymph node areas.21 Concerning concomitant
chemotherapy, weekly single-agent cisplatin at 40 mg/mq dur-
ing EBRT has been widely used to enhance the effect of RT.1
Interestingly, in the present study, analyzing clinical out-
comes grouping based on the stage of disease, the 3-year LC
was not satisfactory for stage III comparing to stage II (67% vs
91%, respectively), suggesting that in this cohort of elderly
patients, stage II was the category of risk that has really bene-
fited this approach. Conversely, in patients with stage III, clin-
ical outcomes could be most dependent on higher-dose effect.
However, the absence of pelvic nodal recurrences in both
stages could be a strength of the study, suggesting that an
higher dose to nodes PET positive by means of SIB approach
could be an effective strategy. Currently, 18FDG PET/CT is
commonly used to detect lymph node involvement and/or dis-
tant metastasis in patients affected by cervical cancer due to its
accuracy and sensitivity for initial staging.22 High radiation
dose to 18FDG PET/CT pelvic-positive nodes by means of
intensity-modulated technique is a feasible treatment with a
potential improvement of locoregional control in cervical
cancer.23
Several shortcomings remain unresolved in the present
study: (1) whether the doses adopted are high enough to allow
a durable LC rate, at least for stage II. Since the biological total
dose of the explored RT schedule remains lower than that
obtained with BRT, the risk of local relapse beyond the median
follow-up of 32 months remains; (2) whether the more homo-
geneous dose distributions achieved with VMAT are as effec-
tive as the inhomogeneous ones produced by BRT; and (3) the
limited sample size, although it is difficult to recruit many
patients 70 years refusing BRT in a single center, because
BRT represents the standard of care that we daily recommend
in this setting of disease.
Conclusion
Weekly cisplatin and VMAT-SIB for radical treatment of
advanced cervical cancer in the current cohort of elderly
patients was feasible. Long-term results and prospective ran-
domized trials are advocated.
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Table 2. Acute and Late Adverse Events, According to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE).
Toxicity
Acute No. Patients (%) Late No. Patients (%)
G0 G1 G2 G3 G4 G0 G1 G2 G3 G4
Gastrointestinal 9 (30) 8 (27) 13 (43) - - 21 (70) 9 (30) - - -
Urinary 7 (23) 12 (40) 11 (37) - - 27 (90) 3 (10) - - -
Vaginal 1 (7) 19 (63) 10 (30) - - 23 (77) 7 (23) - - -
Rectal 14 (47) 9 (30) 7 (23) - - 22 (73) 6 (20) 2 (7) - -
Hematologic 20 (70) 10 (30) - - - 26 (87) 4 (13) - - -
Figure 3. Kaplan-Meier curves grouping based on stage of disease II versus III: (A) overall survival, (b) local control.
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